Why Are Erytech Pharma Shares Soaring Tuesday Premarket?

Erytech Pharma SA ERYP shares gained more than 40% during the premarket trading session.
Investors are probably reacting to the U.S. patent covering methods of treating solid tumors by administering methioninase and asparaginase.
In total, Erytech's IP portfolio now includes 16 global patent families with over 310 patents and 45 applications.
These patent families protect Erytech's proprietary red blood cell encapsulation technology (Erycaps), its therapeutics for Oncology, Rare Metabolic Diseases, Immune Modulation, and production methods Cargo-Loaded Red Cell Extracellular Vesicles.
As disclosed in the patent, Erytech scientists determined that certain solid tumors, including gastric cancer, were unexpectedly sensitized to treatment with asparaginase after prior treatment with methioninase.
Price Action: ERYP shares are up 34% at $3.21 during the premarket session on the last check Tuesday.